前列腺体积与5α还原酶抑制剂对主动监测前列腺癌分级进展及治疗决策的影响
该回顾性队列纳入1938例Grade Group 1前列腺癌主动监测患者,分析前列腺体积及5-ARI使用与分级进展、膀胱出口手术及根治性治疗的关系。结果显示前列腺体积每增加10cc,分级进展风险降低(HR 0.89),5-ARI每使用一年与分级进展(HR 0.80)及根治治疗(HR 0.53)风险降低相关。
要点
- 前列腺体积较大与分级进展及根治性治疗风险降低相关。
- 5-ARI使用与分级进展及根治性治疗风险降低相关。
- BPH症状在主动监测期间可安全管理,包括使用5-ARI。
核心结论
- 在低级别前列腺癌主动监测患者中,前列腺体积增大与分级进展和接受根治性治疗风险降低相关。
- 5-ARI使用与分级进展、极端分级进展及根治性治疗风险降低相关。
- BPH症状在主动监测期间可安全管理,包括使用5-ARI。
研究设计与样本
- 回顾性队列研究,纳入1938例Grade Group 1且接受主动监测的前列腺癌患者。
- 采用多变量扩展Cox模型分析前列腺体积(确认活检时)和5-ARI使用与三种结局的关联。
主要发现
- 前列腺体积<30cc者占14%,30-80cc者占73%,>80cc者占14%。
- 前列腺体积>80cc者更可能接受膀胱出口手术(P < .001)。
- 前列腺体积每增加10cc,分级进展风险降低(HR 0.89,95% CI 0.85-0.93,P < .001)。
- 前列腺体积每增加10cc,接受前列腺癌治疗风险降低(HR 0.91,95% CI 0.88-0.95,P < .001)。
- 5-ARI每使用一年,分级进展风险降低(HR 0.80,95% CI 0.72-0.89,P < .001),极端分级进展风险降低(HR 0.84,95% CI 0.73-0.97,P = .02),前列腺癌治疗风险降低(HR 0.53,95% CI 0.41-0.67,P < .001)。
临床怎么用
- 对于主动监测的低级别前列腺癌患者,前列腺体积和5-ARI使用情况可辅助评估分级进展及治疗决策风险。
- BPH症状在主动监测期间可安全管理,包括使用5-ARI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the impact of prostate volume and 5-alpha reductase inhibitor (5-ARI) use on oncologic outcomes and benign prostatic hyperplasia management among patients undergoing active surveillance (AS) for low-grade prostate cancer (PCa). MATERIALS AND METHODS: We retrospectively reviewed patients with Grade Group (GG) 1 disease on AS. Multivariable extended Cox models examined the associations between prostate volume (at confirmatory biopsy), 5-ARI use, and 3 outcomes: grade progression (GP) on biopsy (to ≥GG 2 and extreme GP to ≥GG 3), receipt of a bladder outlet procedure, and definitive PCa treatment. RESULTS: Among 1938 patients, 14% had prostate volumes < 30 cc, 73% had 30 to 80 cc, and 14% had > 80 cc. Patients with prostate volumes > 80 cc were more likely to undergo bladder outlet procedures (P < .001). On multivariable analysis, increasing prostate volume was associated with decreased rates of GP (HR 0.89, 95% CI 0.85-0.93, P < .001) and PCa treatment (HR 0.91, 95% CI 0.88-0.95, P < .001) per 10 cc; and 5-ARI use (per year) was associated with significant reductions in GP (HR 0.80, 95% CI 0.72-0.89, P < .001), extreme GP (HR 0.84, 95% CI 0.73-0.97, P = .02), and PCa treatment (HR 0.53, 95% CI 0.41-0.67, P < .001). CONCLUSIONS: Among patients with low-grade PCa on AS, increased prostate volume was associated with lower risks of GP and receipt of definitive PCa treatment. Benign prostatic hyperplasia symptoms can safely be managed on AS, including with 5-ARIs, which were associated with lower risks of GP and progression to definitive treatment in this cohort.
引用
- Campbell JA, Ali D, Rezaee ME, et al. The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients With Prostate Cancer on Active Surveillance. J Urol. 2026. PMID: 42341197. doi:10.1097/JU.0000000000005182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。